China NMPA Product Recall - Glucose/Lactate/Urea Electrode Box

Roche Diagnostics Products (Shanghai) Co., Ltd. initiated a voluntary Class II recall for its Glucose, Lactic Acid, and Urea Electrode Kits (Registration No. 20142403745), as announced by the National Medical Products Administration (NMPA) on July 27, 2017. The recall was prompted by an internally identified software issue that could lead to inaccurate urea value detection on Roche cobas b 221 and OMNIS blood gas, electrolyte, and biochemical analyzers. This flaw potentially causes lower or higher recovery rates for urea sample and quality control results, though glucose and lactate measurements are unaffected. No customer complaints were received globally; the problem was discovered during the company's internal studies.

In response, Roche Diagnostics implemented corrective actions. Affected customers received notification letters advising them to repeat sample testing until a permanent resolution is in place. The main action involves installing a software upgrade, issued by the company's headquarters, on all affected analytical systems. This recall prioritizes software-based remediation and customer guidance, rather than the physical withdrawal of products, and adheres to the NMPA's medical device regulatory oversight.